Steris
About: Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Employees: 18,179
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
46% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 48
41% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $8.85M
3% more funds holding
Funds holding: 716 [Q1] → 738 (+22) [Q2]
3% more repeat investments, than reductions
Existing positions increased: 280 | Existing positions reduced: 271
0% more funds holding in top 10
Funds holding in top 10: 8 [Q1] → 8 (+0) [Q2]
5% less capital invested
Capital invested by funds: $22B [Q1] → $20.9B (-$1.14B) [Q2]
17.84% less ownership
Funds ownership: 114.42% [Q1] → 96.58% (-17.84%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Keybanc Brett Fishbin 72% 1-year accuracy 13 / 18 met price target | 18%upside $265 | Overweight Maintained | 3 Sept 2024 |
JMP Securities David Turkaly 45% 1-year accuracy 10 / 22 met price target | 18%upside $265 | Market Outperform Reiterated | 7 Aug 2024 |
Stephens & Co. Jacob Johnson 43% 1-year accuracy 6 / 14 met price target | 16%upside $260 | Overweight Reiterated | 7 Aug 2024 |
JMP Securities David Turkaly 45% 1-year accuracy 10 / 22 met price target | 18%upside $265 | Market Outperform Reiterated | 26 Jul 2024 |